Cost of new drug challenged

Home/Pharma News | Posted 21/01/2011 post-comment0 Post your comment

An editorial in the New England Journal of Medicine (NEJM) issue of 23 September 2010 took the unusual position of challenging a study published in the same issue.

picture20

The challenge from Dr Lee Goldman and Dr Jeffrey Ginsberg in their editorial focussed around the cost of the treatment compared to the relative benefit, a growing debate in American medicine.

The study published in the NEJM proved that a blood-thinning medicine could prevent problems from worsening in some people with a sometimes painful, usually short-term and non-fatal, blood clot near the surface of the leg, called superficial-vein thrombosis.

The editorial, however, challenged the costs of the treatment (ranging from US$2,124–7,380 per patient to receive injections for 45 days) to prevent one out of 88 patients from having a more dangerous, but rarely fatal, deep vein clot.

The issue of cost-effectiveness is becoming a hot topic as more Americans become eligible for Medicare insurance, drug rebates increase and new healthcare reform aims to bring affordable health care to 30 million more people by 2019.

Healthcare expenditure in the US is already higher than any other country, and currently spends about 18% of the gross domestic product on health care.

Related article

US healthcare reform

Source: NEJM, New York Times.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010